Skip to content
DataLookout
Menu

NCT07293247

A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

StatusRecruiting
PhasePhase 2
Primary completion (estimated)

At risk: Primary completion moved 4 years later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 9 versions: 8 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 111 → 125 locations
  2. Notable Primary completion pushed from Dec 31, 2028 to Dec 31, 2032
    • Study completion pushed from Mar 1, 2032 to Mar 1, 2036
  3. Notable Eligibility criteria expanded, about 22 words
    • Trial sites expanded: 97 → 111 locations
    • Secondary endpoints: details revised at 4 of 4 entries
    • Study description revised
  4. Notable Start date: Jul 14, 2026 to Oct 14, 2026
    • Trial sites expanded: 74 → 97 locations
    v6
  5. Minor Trial sites expanded: 33 → 74 locationsv5
  6. Minor Trial sites expanded: 28 → 33 locationsv4
  7. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date: Mar 14, 2026 to Jul 14, 2026
    • Study sites: 0 to 28
    v3
  8. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Disease-free survival (DFS)
Timeframe: Time from the date of randomization to the date of earliest disease recurrence/progression or deaths of all causes, assessed up to 5 years
Incidence of late grade ≥ 3 cardiopulmonary toxicities
Timeframe: Between 3 and 24 months after protocol therapy

Secondary (4)

5-year DFS
2-year overall survival (OS)
5-year OS
Patient-reported symptoms

Arms and interventions

Arm I (SOC chemotherapy/immunotherapy)Active comparator

Patients receive SOC chemotherapy or immunotherapy on study. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and/or MRI, FDG-PET, and blood sample collection throughout the study.

Arm II (I²-PORT, SOC chemotherapy/immunotherapy)Experimental

Patients undergo I²-PORT QD Monday through Friday over 15-25 fractions over 5-6 weeks. Starting 1-42 days after completion of I²-PORT, patients receive SOC chemotherapy or immunotherapy on study. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and/or MRI, FDG-PET, and blood sample collection throughout the study.

Drugs: Chemotherapy

Other: Immunotherapy, Fludeoxyglucose F-18

Radiation: Intensity-Modulated Radiation Therapy

Procedures: Computed Tomography, Magnetic Resonance Imaging, Biospecimen Collection

Sites

125 sites in 1 country